www.fortyseveninc.com
About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact [email protected].
For journalist enquiries please contact Sarah Plumridge at [email protected] or phone (312) 506-5218.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at [email protected] or phone (212) 362-1200.
[ Back To TMCnet.com's Homepage ]